Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week.
- Atriva received €3M as a milestone from its investors for a preclinical development step towards an antiviral flu treatment.
- Alcon handed global rights to Jetrea, a retinal disorder treatment, back to Thrombogenics, whose stock jumped 15% following the announcement on Monday morning.
- Synpromics, our Scottish former biotech of the week, has joined Solid Biosciences in a gene therapy research partnership to develop new Duchenne muscular dystrophy treatments
- Pharnext changed its Phase III pivotal trial protocol for PXT3003 in Charcot-Marie-Tooth Disease, but there were no safety issues, and milestones have not been changed.
- Trefyma, licensed by Morphosys to Janssen, will start two new Phase III studies in Psoriatic Arthritis
- Sanofi is manufacturing a trispecific antibody as an HIV treatment for the NIH: the French pharma just reported that it protected monkeys against the simian equivalent of the disease and performed better than three individual antibodies.
- VarmX, a biotech drawing inspiration from snake venom to restore blood clotting, announced the publication of preclinical results in Nature Communications
- The Canadian-European Trade Agreement (CETA) has taken effect. Leaders hope it will save everyone taxes and make business smoother.
- Lysogene held its first Parent Advisory Board for a rare childhood disease to better understand its patients’ needs.
- OncoQR ML has announced its vaccine platform can activate immunological pathways through broad checkpoint control
Images via Parkol, Tilo G, Nacho Such / shutterstock.com